Clinical Utility of an In-House Targeted Sequencing Panel Compared to Commercial Comprehensive Genomic Profiling for Solid Tumors

AMP 2025

Nov 11, 2025
Oncology
Abstract

T. Wang, K. Shenoy, P. Hernandez, E. Duncavage, A. Hughes, L. Sun

Introduction
Somatic tumor profiling through next-generation

 

sequencing (NGS) has become common practice for prognostication and

 

therapy selection. Comprehensive genomic profiling (CGP) is an approach

 

that assesses hundreds of genes and mutational signatures, and may

 

include both DNA and RNA sequencing. In contrast, targeted NGS panels

 

often evaluate a subset of these targets. We hypothesized that for some

 

tumor types, a targeted panel is sufficient to make biomarker-informed

 

therapy decisions. Methods: We validated an in-house, DNA-only,

 

targeted NGS panel, GatewaySeq, that includes less than 50 relevant

 

genes per tumor type. We retrieved retrospective cases from 2023 to

 

2025 that had both GatewaySeq as well as a CGP assay (Tempus xT or

 

Caris MiProfile) ordered, and compared concordance of variants detected.

 

In addition, we evaluated the electronic medical record to determine

 

whether sequencing results from each assay affected management

 

decisions. Results: Thirty-three cases were assessed (17 non-small cell

 

lung cancers, 7 breast carcinomas, 4 endometrial cancers, 3

 

gastrointestinal stromal tumors, 1 ovarian cancer, and 1 cancer of

 

unknown primary). Altogether, the CGP assays reported 127 biologically

 

or clinically significant variants, whereas GatewaySeq reported 91

 

significant variants, with a concordance rate of 76/142 (53.5%). Fifty

 

(35.2%) single nucleotide variants (SNVs) and copy number alterations

 

(CNAs) were reported as significant by CGP, although their corresponding

 

genes were not included in the GatewaySeq panel; none of these were

 

variants associated with eligibility for or resistance to approved targetable

 

therapies. One SNV and 4 CNAs were reported by GatewaySeq but not

 

by CGP. Only 1 variant, a PTEN loss, was included as a validated target

 

in both assays but was not detected by GatewaySeq. Six cases were

 

quantity not sufficient (QNS) by CGP but sufficient by GatewaySeq, even

 

though 2 of the cases had GatewaySeq ordered on the same block after

 

CGP was attempted. GatewaySeq reported variants associated with

 

tumor-specific approved targeted therapies for 4 of the CGP-QNS cases.

 

In total, 16/33 (48.5%) cases had a variant with tumor-specific therapeutic

 

implications; in 9 (27.2%) of these cases the NGS result informed the

 

patient’s subsequent treatment. There were no changes in management

 

based on the additional variant and mutational signature information from

 

the CGPs that was not present in GatewaySeq. Conclusions: A small,

 

targeted NGS panel is sufficient for therapeutic decision-making in lung

 

cancer, breast cancer, and gastrointestinal stromal tumors. A tiered

 

approach to somatic tumor profiling could begin with testing by a targeted

 

panel, followed by CGP if needed for clinical trial eligibility.